Compelling evidence has suggested that the reactive CD8+ TILs from lung cancer patients become dysfunctional with impaired cytokine production and compromised proliferative capacity in the context of a broad spectrum of immunosuppressive signals occurring in the tumour microenvironment.3 The gene discussed is CD8A; the disease is lung cancer.